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Background: Peripheral neuropathy symptoms (PNS) are commonly manifested in HIV-infected (HIV+) individuals, 
although data are limited on the prevalence and predictors of  PNS in HIV+ patients from sub-Saharan Africa.
Objective: To determine the prevalence and predictors of  PNS in HIV+ and HIV-uninfected (HIV-) Rwandan women.
Methods: Data were analysed from 936 (710 HIV+ and 226 HIV-) women from the Rwanda Women Interassociation Study 
and Assessment (RWISA), an observational prospective cohort study investigating the effectiveness and toxicity of  ART in 
HIV+ women.
Results: Of  936 enrolled, 920 (98.3%) were included in this analysis with 44% of  HIV- and 52% of  the HIV+ women 
reporting PNS (p=0.06). CD4+ count was not associated with PNS, although there was a non-significant trend towards 
higher prevalence in those with lower CD4+ counts. For the HIV- women, only alcohol and co-trimoxazole use were 
independently associated with PNS. WHO HIV stage IV illness and albumin ≤ 3.5 were associated with PNS in HIV+ 
women. 
Conclusions: The rate of  peripheral neuropathy symptoms reported in this cohort of  HIV-infected African women seems 
implausible, and rather suggests that the screening tool for peripheral neuropathy in culturally diverse African settings be 
locally validated.
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Introduction 
About 60% of  patients with advanced HIV disease 
clinically develop evidence of  neurological dysfunction 
during the course of  their illness1, 2. Peripheral 
neuropathies, specifically sensory neuropathies, are the 
most common neuromuscular complications in HIV-
infected (HIV+) patients. Peripheral neuropathy is 
common in HIV+ African populations, with prevalence 
ranging from 15% - 50%3,4,5,6. 
Several risk factors have been associated with peripheral 
neuropathy, including older age, advanced HIV disease 
and history of  combination antiretroviral therapy (cART) 
or other neurotoxic drugs7,8,9. Although the introduction 
of  cART has dramatically reduced mortality rates of  
people living with HIV infection, its use has been 
associated with increased peripheral neuropathy10. The 
antiretroviral agents most associated with peripheral 
neuropathy, are the “d” drugs: didanosine (ddI, rarely 
used), deoxycytosine (ddC, now not manufactured) 
and stavudine (d4T, very commonly used but has 
been reduced currently)9. The substantially improved 
life expectancy that cART creates for HIV infected 
individuals may be compromised by complications of  
therapy, including peripheral neuropathy. The aetiology 
of  HIV- and cART-associated peripheral neuropathy 
symptoms is unclear, although the neurotoxic effects of  
cytokines, toxicity of  HIV proteins and mitochondrial 
damage have been implicated5. 
However, although some studies have reported 
peripheral neuropathy, there are inadequate studies on 
predictors of  peripheral neuropathy symptoms in HIV-
infected African patients, where the burden of  HIV 
infection is the highest, and cART is gradually becoming 
more available. As there are limited studies in African 
countries including Rwanda on the prevalence and 
predictors of  peripheral neuropathy symptoms in HIV-
infected individuals, there is a need to understand better 
factors associated with peripheral neuropathy symptoms 
in HIV-infected compared to HIV uninfected (HIV-) 
African individuals. We examined the prevalence of, and 
factors associated with peripheral neuropathy symptoms 
in antiretroviral-naïve HIV-infected and uninfected 
Rwandan women participating in the Rwanda Women’s 
Interassociation Study and Assessment (RWISA). The 
findings from the study are important to inform policy 
on appropriate management of  the disabling peripheral 
neuropathy symptoms particularly among women 
in whom HIV infection prevalence rate is highest in 
resource limited African countries including Rwanda. 
Methods
Study Design and Setting 
This was a cross-sectional analysis of  enrolment data 
on the prevalence of, and factors associated with PNS 
among 936 (710 HIV+ and 226 HIV-) Rwandan women 
in the Rwanda Interassociation Study and Assessment 
(RWISA) study, enrolled in 2005 with follow-up 
visits every six months. RWISA was an observational 
prospective cohort study investigating the effectiveness 
and toxicity of  ART in HIV-infected Rwandan women. 
Women who volunteered to participate were recruited 
from grassroots associations of  people living with 
HIV infection attending various HIV clinics in Kigali. 
Participants were included if  they were >25 years old, 
willing to undergo voluntary counselling and testing for 
HIV, present in Rwanda since 1994, and willing to return 
for follow-up; HIV-positive women were required to 
be naïve to ART, except for exposure to single-dose 
nevirapine to prevent mother-to-child HIV transmission. 
Each woman provided written informed consent. The 
study protocol was approved by the Rwanda National 
Ethics Committee and the Institutional Review Board 
of  Montefiore Medical Center, Bronx, NY USA. At 
study entry, participants provided historical information 
including medical history, demographic parameters, 
psychosocial history, experience of  trauma during the 
1994 Rwandan genocide, and symptoms of  depression 
and posttraumatic stress. A physical examination was 
performed and specimens were taken for CD4 count, 
full blood count, and other laboratory studies.  Methods 
for the RWISA study have been previously described in 
detail11. 
Participants were interviewed by trained research nurses 
on several items including symptoms of  peripheral 
neuropathy in the previous six months, ascertained 
by the validated question, “In the past six months, have 
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you experienced numbness, tingling, or burning sensations in 
your arms, legs, hands, or feet that lasted for more than two 
weeks?”10. Participants also provided socio-demographic 
characteristics, and a physical examination was 
performed. Blood specimens were taken for full blood 
count and CD4+ count determination measured at the 
National Reference Laboratory of  Rwanda by FACS 
Count. 
Statistical Analysis
Associations of  peripheral neuropathy symptoms 
with HIV status and CD4+ counts were assessed by 
Fisher’s exact and chi-square tests for categorical, 
and Kruskal Wallis tests for continuous variables. 
Separate univariate logistic regression models were fit 
to associations between predictor variables of  interest, 
and peripheral neuropathy symptoms for HIV infected 
and uninfected women. For each HIV infection status 
group, the variables statistically significant at p<0.1 in 
the univariate model for the group were included in a 
multivariate logistic regression model for that group 
to further test for independent predictive associations 
with peripheral neuropathy symptoms.
Results 
Participant Demographic Characteristics 
Participants’ demographic characteristics are illustrated 
in Table 1. Of  936 women who participated in the 
RWISA study, 920 (98.3%) had answered the peripheral 
neuropathy question, and were thus included in this 
analysis: 704 HIV+ and 216 HIV-. 
Table 1: Demographic and Clinical Characteristics by HIV serostatus and CD4 cell count















Age in years n (%)
<30 34 (15) 51 (26) 50 (19) 57 (24) <0.001 158(22)
30-40 59 (26) 105 (54) 150 (56) 133 (55) 388(55)
40+ 133 (59) 39 (20) 67 (25) 52 (21) 158 (22)
Income/month/ Rwf  
 N (%)
<10k 91 (45) 66 (34) 98 (37) 87 (37) 0.07 251 (36)
10 – 35k 79 (39) 105 (54) 130 (49) 111 (47) 346 (50)
>35k 33 (16) 22 (11) 35 (13) 40 (17) 97 (14)
Education n(%)
No schooling 67 (32) 46 (24) 58 (22) 52 (22) 0.16 156 (22)
Some primary school 68 (32) 78 (40) 98 (37) 92 (38) 268 (38)
Secondary or University 76 (36) 71 (36) 110 (41) 96 (40) 277 (40)
Marital status n (%)
Legally married/partner 80 (38) 86 (44) 96 (36) 73 (30) 0.001 255 (36)
Widowed 107 (50) 71 (36) 118 (44) 107 (44) 296 (42)
Other 25 (12) 38 (10) 53 (20) 62 (26) 153 (22)
Body Mass index 
Blood Pressure mean±SD
Systolic 119±15 117±9 117±11 115±11 0.009 116±10
Diastolic 74±10 72±7 71±8 71±8 0.02 71±7
Alcohol, n(%) 56 (28) 39 (21) 52 (20) 52 (22) 143 (21)
Smoking,  n(%) 7 (3) 4 ( 2) 7 (3) 7 (3) 18 (3)
Albumin, mean±SD 3.9±0.5 3.6±0.6 3.5±0.7 3.3 ±0.7 <0.001 3.4±0.6
Creatinine,  mean±SD 0.85±0.18 0.90 ±0.2 0.92 ±0.19 0.93±0.18 <0.001 0.92 ±0.19
Self-reported PNS n(%) 96 (44) 93 (48) 138 (52) 133 (55)   0.12 364 (52)
WHO stage 4 condition,  n(%) 32 (15) 59 (30) 105 (39) 124 (51) <0.001 228 (41)
Pulmonary TB,  n(%) 4 (2) 20 (10) 28 (10) 44 (18) <0.001 92 (13)
Any prior TB,  n(%) 4 (2) 20 (10) 31 (12) 46 (19) <0.001 97 (14)
Dapsone use 1 ( 1) 1 (0.4) 1 ( 0.4) <0.001 3( 0.4)
Bactrim use 41 (19) 145 (75) 246 (92) 220 (91) <0.001 611 (87)
Albumin <3.5  gm/dL 44 (21) 75 (41) 130 (51) 146 (63) <0.001 351 (52)
Creatinine >1.2 gm/dL 4 (2) 7 (4) 14 (6) 17 (7) 0.026 38 (6)
Isoniazid, prior use 8 (4) 15 (6) 20 (8) <0.001 43 (6)
Data presented as n (%) or mean ±SD; 1 US$=600 Rwf; TB, tuberculosis; WHO World Health Organization; *the p-value 
refers to the 4-group difference (HIV-, CD4 > 350, CD4 200-350 and CD4 < 200)
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The HIV+ women were younger than HIV- women 
(p<0.001). The HIV- women were more likely to be 
widowed (p=0.004), had higher systolic (p=0.045) and 
diastolic blood pressure (p=0.006), but were less likely 
to report prior pulmonary tuberculosis (p<0.001) than 
the HIV+ women (Table 1). Mean creatinine levels, 
having albumin <3.5 gms/dL (p<0.001) or creatinine 
> 1.0 mg/dL and any prior use of  isoniazid (p<0.001) 
were higher in HIV+ women (Table 1). 
Prevalence of  peripheral neuropathy symptoms
Symptoms of  peripheral neuropathy were reported 
by 44% of  the HIV- and 52% of  the HIV+ women 
(p=0.06). There was a statistically non-significant trend 
toward higher prevalence in HIV+ women with lower 
CD4+ in the categories >350, 200-350, and <200 cells/
µl (48%, 52% and 55% respectively) (p=0.32).
Factors predicting peripheral neuropathy symptoms 
in HIV- women
Because of  the unexpectedly high prevalence of  
reported PNS in the HIV- women, we developed 
separate statistical models for the HIV- and HIV+ 
women. Table 2 illustrates factors that predicted PNS 
in HIV- women in univariate and multivariate analysis. 
In univariate analysis, PNS in the HIV- women was 
associated with lower income, being reported by 55% 
and 27% of  the women with income <10,000 FRW and 
>35,000 FRW respectively (p=0.02). But income was 
not independently associated with PNS among HIV- 
women in multivariate analysis (Table 2). Only alcohol 
and co-trimoxazole use were independently associated 
with PNS among HIV- women in multivariate analysis: 
alcohol [aOR= 2.40, 95% CI (1.22, 4.69), p=0.01] 
and co-trimoxazole [aOR= 2.25, 95% CI (1.08, 4.69), 
p=0.03] (Table 2). 
Table 2: Univariate and multivariate associations of  demographic and clinical characteristics with 
peripheral neuropathy in HIV uninfected women 
Characteristic Prevalence (%) of  
self-reported PNS
(n=96)




p-value Adjusted  Odds 




<30 11 (32%) 0.10
30-40 22 (39%) 1.31 1.34 (0.51, 3.54) 0.56
0.1240+ 63 (50%) 2.12 2.11(0.83, 5.36)
Income 
< 10 k Rwf 50 (55%) 0.020
10 - 35 k Rwf 34 (43%) 0.73 0.76 (0.39,1.47) 0.41





Widowed 55 (51%) 1.56 0.89 (0.42, 1.85) 0.75
0.28Other 7 (28%) 0.57 0.55 (0.19, 1.61)
Alcohol 
       No 56 (38%)
      Yes 35 (62%) 2.68 0.002 2.40 (1.22, 4.69) 0.01
Albumin, per mg/dl 
      n (mean ±SD) 91(3.89±0.47) 0.76 0.27
Tuberculosis ever
       No 95 (45%)
      Yes 1 (25%) 0.41 0.43
Cotrimoxazole use
       No 70 (40%)




Yes 3 (75%) 3.96 0.20
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Table 3: Univariate and multivariate associations of  demographic and clinical characteristics with 
peripheral neuropathy symptoms in HIV- infected women
Parameters Prevalence (%) 
of  PNS
(n=364)









CD4 > 350 92 (48) 0.32
0.69
0.83
CD4 200-350 138 (52) 1.17 1.08 (0.73, 1.60)
CD4 <200 133 (55) 1.34 1.05 (0.70, 1.58)
Age/years (%)
<30 78 (49) 0.32
30-40 201 (52) 1.10
40+ 85 (54) 1.19
Income 
< 10 k Rwf 144 (57%) 0.09
10 - 35 k Rwf 169 (48%) 0.73 0.90 (0.64,1.28) 0.56
> 35 k Rwf 47 (48%) 0.72 0.87 (0.51,1.41) 0.52
Level of  education n 
(%)
No schooling 97 (62)
0.02Some primary school 131 (49) 0.56 0.01 0.60 (0.40, 0.92)
Secondary or University 133 (48) 0.55 0.59 (0.39, 0.91) 0.02
Systolic  (per 10 mg 
Hg)
N (mean ±SD) 364(11.59 ±1.0) 0.936 0.40
Diastolic (per 10 mg 
Hg) 
n (Mean ±SD) 364(7±0.73) 0.907 0.59
Alcohol 
No 277 (52)
Yes 71 (50) 0.911 0.62
Smoking 
No 354 (52)
Yes 10 (56) 1.171 0.74
Albumin 
345
n (mean ±SD) 3.34±0.64 0.650 0.002
WHO stage IV 
No 185 (44)
Yes 179 (62) 2.05 <0.001 1.84 (1.33, 2.55) ≤0.001
Ever any TB
No 306 (50)
Yes 58 (60) 1.46 0.09 1.24 (0.78, 1.97) 0.36
Bactrim 
No 48 (53)
Yes 315 (52) 0.95 0.83
Albumin ≤3.5
No 143 (45)
Yes 202 (58) 1.69 <0.001 1.52 (1.10, 2.09) 0.01
Multivariate model does includes “any TB ever”, but not “Pulmonary TB”
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Factors that predicted PNS in HIV-positive women
Covariates associated with PNS were also assessed in 
HIV+ women in both univariate and multivariate models 
(Table 3). While there was no significant association of  
CD4+ count with PNS, other markers of  advanced HIV 
disease progression demonstrated a strong independent 
association with PNS in multivariate analysis: WHO 
HIV stage IV [aOR; 1.84 95% CI (1.33, 2.55), p<0.001] 
and albumin ≤ 3.5 [aOR; 1.52 95% CI (1.10, 2.09), p= 
0.01]. Educational attainment was lower in the women 
with PNS (no schooling; 62% vs 48%, p=0.01) in both 
unadjusted analysis and the multivariate model. Use 
of  alcohol and co-trimoxazole were not statistically 
associated with PNS in the HIV+ women.
Discussion
We observed a strangely high prevalence of  self-reported 
peripheral neuropathy symptoms in HIV-infected 
and uninfected Rwandan women. While peripheral 
neuropathy symptoms are common neurological 
complications of  HIV infection12,13 the high prevalence 
in both groups suggests possible over-reporting of  
peripheral neuropathy in this cohort. In particular, we 
believe it is unlikely that true peripheral neuropathy was 
present in 44% of  HIV uninfected women. The item 
used to identify peripheral neuropathy symptoms, “In 
the last six months have you experienced numbness, tingling, or 
burning sensations in your arms, legs, hands or feet that lasted for 
more than 2 weeks?” may have not been specific to identify 
only peripheral neuropathy symptoms that occurred in 
the previous 6 months and lasted at least for 2 weeks. 
There is a cultural practice in Rwanda of  describing 
“tired legs” as pain and numbness, and this may have 
resulted in misunderstanding of  the assessment of  
peripheral neuropathy. Therefore, the feeling of  “tired 
legs”, often conceived as muscle cramps, may have been 
misconceived for peripheral neuropathy symptoms 
by the HIV uninfected women among whom the 
prevalence of  peripheral neuropathy symptoms seem 
to have been over-reported.
Our own scepticism about the high prevalence of  
peripheral neuropathy symptoms among the HIV 
uninfected women prompted us to informally ask the 
nurses who conducted data collection to know whether 
the question on occurance of  peripheral neuropathy 
was well understand, and interpreted well to participants 
during the study when the nurses conducted RWISA 
nurses-guided interviews. One additional probable 
reasons for this over reporting of  peripheral neuropathy 
symptoms they suggested was that “….the peripheral 
neuropathy symptoms … lasted for more than 2 weeks?” 
was misunderstood for “…the peripheral neuropathy 
symptoms…in the last 2 weeks?” meaning perhaps 
something such as a single event of  tingling due to poor 
circulation could have been misreported as peripheral 
neuropathy symptoms. 
Our findings on the prevalence of  peripheral neuropathy 
among the HIV-infected women are similar to a South 
African study in which the prevalence of  peripheral 
neuropathy symptoms was 49%, and was associated with 
older age, use of  ART and report of  prior tuberculosis14. 
However, the South African study did not include HIV 
uninfected women for comparison, and may have similar 
over-reporting of  peripheral neuropathy among the HIV-
infected women. In spite of  the potential over-reporting 
of  peripheral neuropathy symptoms in HIV-uninfected 
participants in our study, the observed prevalence of  
self-reported peripheral neuropathy symptoms in the 
HIV-infected women is in agreement with other studies 
from both African and Western countries. Reports 
from Western countries suggest that the prevalence 
of  peripheral neuropathy symptoms in HIV-infected 
individuals is within the range of  35 - 52%, and its 
prevalence in HIV-infected ART-naïve patients may be 
higher among those with lower CD4+ cell counts12,13. 
Our findings differ from one African study from 
Guinea-Bissau in HIV-infected and HIV-uninfected 
controls in which presence of  peripheral neuropathy 
was predicted by older age and higher body mass index 
(BMI)15. However, the 45% reported prevalence of  
peripheral neuropathy symptoms reported in Guinea-
Bissau is similar to our findings15. One study reported 
presence of  peripheral neuropathy symptoms in 69% 
of  HIV-infected patients using clinical examination, 
with only 33% prevalence of  symptoms using more 
objective assessment with electro-neuromyography13. 
The prevalence of  peripheral neuropathy for the HIV-
infected women in our study is similar on average with 
the prevalence of  peripheral neuropathy assessed by 
clinical examination and electro-neuromyography. 13 
Noting this, it is interesting to observe that, if  we had 
not included an HIV-negative cohort, our results would 
have been relatively unquestionable. Inclusion of  a 
control group when using screening tools developed 
elsewhere may be a useful mechanism for ensuring valid 
results. 
In the HIV-infected women, peripheral neuropathy 
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symptoms were not associated with HIV disease 
progression, as neuropathy symptoms were not related 
with CD4+ counts category.  We observed a significant 
association of  low serum albumin levels with presence 
of  peripheral neuropathy symptoms in HIV-infected 
women. In a study population from New York, lower 
albumin levels were associated with a common type 
of  peripheral neuropathy, the distal symmetrical 
polyneuropathy, which was reported in 38% of  HIV-
infected patients16. However, the study further reported 
an association of  peripheral neuropathy symptoms 
with older age.16 However, in the RWISA cohort, our 
group have previously reported that serum albumin was 
a marker of  clinically more advanced HIV disease17. 
Similarly, HIV advanced disease (WHO Stage III and 
IV) was associated with greater peripheral neuropathy. 
The severity of  HIV disease was also associated with 
distal sensory polyneuropathy in a Greek study in 
which WHO HIV stage IV illness and older age were 
associated with peripheral neuropathy symptoms18. 
Our study is limited by the investigators’ concerns 
concerning the validity of  the screening question, 
its cross-sectional design, and thus inability to make 
inferences about causality, especially as there was 
seemingly over-reporting of  high rates of  reported 
peripheral neuropathy in the HIV uninfected women. 
Secondly, our study was limited by its use of  self-
reported symptoms of  peripheral neuropathy, rather 
than an objective assessment measure.
In conclusion, peripheral neuropathy symptoms are 
common in HIV-infected antiretroviral-naïve Rwandan 
women, when using this broad screening question. Due 
to potential for over-reporting of  PNS symptoms, we 
suggest the use of  more rigorous and culturally-specific 
assessment of  peripheral neuropathy detection tools 
that would need to be validated and used in different and 
across African settings. Inclusion of  HIV-uninfected 
controls will also help to determine if  prevalence of  
HIV-associated peripheral symptoms are overestimated. 
If  this is not feasible, then investigators must be cautious 
in interpreting self-reported symptoms across cultures.
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